Biotechnology

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

A Boston-area biotech is tackling a key bottleneck in drug manufacturing, promising to unlock a new generation of RNA therapeutics with its novel platform.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

From lab breakthroughs to Hollywood advocacy, the 2026 Reeve Summit showcases a powerful, multi-front strategy to cure paralysis and enrich lives today.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

A Belgian firm's new biologic gel for diabetic foot ulcers gets a key FDA green light, offering hope against a leading cause of amputations.

As its oesophageal cancer vaccine enters trials, Infinitopes hires a top CSO with a track record of bringing breakthrough therapies to market.

A new partnership leverages an FDA-designated analytics platform to solve critical AAV manufacturing hurdles, promising safer, more reliable gene therapies.

By automating the production of a groundbreaking immune therapy, a new collaboration could finally unlock the full potential of personalized medicine for cancer.

A renewed alliance aims to break key supply chain bottlenecks in gene therapy, offering developers faster access to critical, regulatory-ready materials.

A new drug targeting the root cause of sebum production shows promise in clinical trials, offering hope for millions of moderate to severe acne sufferers.

Actuate Therapeutics gets FDA nod for its oral cancer drug elraglusib, shifting strategy to improve patient outcomes and tackle hard-to-treat tumors.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

OncLive® unveils its 2026 class of inductees, 14 visionaries whose groundbreaking work is transforming the future of oncology and bringing hope to millions.

As BioPharma races to adopt AI, fragmented data remains a huge hurdle. A Boston forum aims to find solutions for building a trusted digital foundation.

For the 8th straight year, Equashield dominates the CSTD market. We explore the tech, trust, and automation driving its success in protecting workers.

With two pivotal trial readouts looming and cash projected to last only into Q4, Tvardi Therapeutics faces a make-or-break year for its STAT3 inhibitors.